<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Assessment of asthma symptom control and risk of exacerbations</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Assessment of asthma symptom control and risk of exacerbations</h1>
<div class="graphic"><div class="figure"><div class="ttl">Assessment of asthma symptom control and risk of exacerbations</div><div class="cntnt"><table cellspacing="0"><colgroup width="41%"></colgroup><colgroup span="2" width="7%"></colgroup><colgroup span="3" width="15%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1_left" colspan="6">A. Level of asthma symptom control</td> </tr> <tr class="divider_bottom"> <td class="indent1" colspan="3"><strong>In the past 4 weeks, has the patient had:</strong></td> <td class="centered"><strong>Well controlled</strong></td> <td class="centered"><strong>Partly controlled</strong></td> <td class="centered"><strong>Uncontrolled</strong></td> </tr> <tr> <td class="indent2">Daytime symptoms more than twice/week?</td> <td><span class="primarybox_left"> </span><br/> Yes</td> <td><span class="primarybox_left"> </span><br/> No</td> <td class="border_bottom_thick centered" rowspan="4">None of these</td> <td class="border_bottom_thick centered" rowspan="4">1 to 2 of these</td> <td class="border_bottom_thick centered" rowspan="4">3 to 4 of these</td> </tr> <tr> <td class="indent2">Any night waking due to asthma?</td> <td><span class="primarybox_left"> </span><br/> Yes</td> <td><span class="primarybox_left"> </span><br/> No</td> </tr> <tr> <td class="indent2">SABA reliever* needed more than twice/week?</td> <td><span class="primarybox_left"> </span><br/> Yes</td> <td><span class="primarybox_left"> </span><br/> No</td> </tr> <tr class="border_bottom_thick"> <td class="indent2">Any activity limitation due to asthma?</td> <td><span class="primarybox_left"> </span><br/> Yes</td> <td><span class="primarybox_left"> </span><br/> No</td> </tr> <tr class="divider_bottom"> <td class="subtitle1_single" colspan="6">B. Risk factors for poor asthma outcomes</td> </tr> <tr class="divider_bottom"> <td class="indent1" colspan="6"> <p>Assess risk factors at diagnosis and periodically, at least every 1 to 2 years, particularly for patients experiencing exacerbations.</p> Measure <span class="nowrap_whitespace">FEV<sub>1</sub></span> at start of treatment, after 3 to 6 months of controller treatment to record personal best lung function, then periodically for ongoing risk assessment.</td> </tr> <tr class="divider_bottom"> <td class="indent1" colspan="5"> <p>Having uncontrolled asthma symptoms is an important risk factor for exacerbations.</p> Additional potentially modifiable risk factors for exacerbations, even in patients with few asthma symptoms, include: <ul class="decimal_heading"> <li><strong>Medications:</strong> ICS not prescribed; poor adherence; incorrect inhaler technique; high SABA use (with increased mortality if <span class="nowrap_whitespace">≥1×200-dose canister/month)<sup>¶</sup></span></li> <li><strong>Comorbidities:</strong> obesity; chronic rhinosinusitis; gastroesophageal reflux disease; confirmed food allergy; anxiety; depression; pregnancy</li> <li><strong>Exposures:</strong> smoking<sup>Δ</sup>; allergen exposure if sensitized; air pollution</li> <li><strong>Setting:</strong> major socioeconomic problems</li> <li><strong>Lung function:</strong> low <span class="nowrap_whitespace">FEV<sub>1</sub>,</span> especially if &lt;60% predicted; higher reversibility</li> <li><strong>Other tests:</strong> sputum/blood eosinophilia; elevated <span class="nowrap_whitespace">FE<sub>NO</sub></span> in allergic adults on ICS</li> </ul> <p class="extra_spacing_top">Other major independent risk factors for flare-ups (exacerbations) include:</p> <ul class="decimal_heading"> <li>Ever being intubated or in intensive care for asthma</li> <li>Having 1 or more severe exacerbations in the last 12 months</li> </ul> </td> <td class="highlight_lght_green_text">Having any of these risk factors increases the patient's risk of exacerbations <strong>even if they have few asthma symptoms</strong>.</td> </tr> <tr class="divider_bottom"> <td class="indent1" colspan="6">Risk factors for developing fixed airflow limitation include preterm birth, low birth weight, and greater infant weight gain; lack of ICS treatment; exposure to tobacco smoke, noxious chemicals, or occupational exposures; low <span class="nowrap_whitespace">FEV<sub>1</sub>;</span> chronic mucus hypersecretion; and sputum or blood eosinophilia</td> </tr> <tr> <td class="indent1" colspan="6">Risk factors for medication side-effects include: <ul class="decimal_heading"> <li><strong>Systemic:</strong> frequent OCS; long-term, high dose and/or potent ICS; also taking cytochrome P450 inhibitors</li> <li><strong>Local:</strong> high-dose or potent ICS; poor inhaler technique</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">Asthma control has two domains: symptom control and risk of future exacerbations. Assess the symptom control domain by patient's recall of previous 4 weeks; assess risk of future exacerbations by the presence of risk factors and by spirometry/or peak flow measures.</div><div class="graphic_footnotes"><p><span class="nowrap_whitespace">FEV<sub>1</sub>:</span> forced expiratory volume in one second; ICS: inhaled corticosteroids; SABA: short-acting beta-2 agonist; <span class="nowrap_whitespace">FE<sub>NO</sub>:</span> fraction of expired nitric oxide; OCS: oral corticosteroid.</p>
<p>* The threshold of two uses per week as a measure of poor control is only appropriate for SABA relievers. Use of anti-inflammatory relievers (eg low-dose ICS-formoterol or ICS-SABA) provides additional ICS therapy and leads to lower risk of subsequent exacerbation than increased SABA alone. However, average weekly use of anti-inflammatory reliever should still be assessed when reviewing need for or dosing of maintenance ICS.</p>
<p>¶ Current guidelines note that use of ≥3 200-dose SABA canisters/year is also associated with increased exacerbation risk.</p>
Δ Smoking includes e-cigarette exposure.</div><div class="graphic_reference">For the most recent version of the GINA assessment of asthma control, please visit: Global
Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2023. Available at: <a href="https://ginasthma.org/2023-gina-main-report/" target="_blank">https://ginasthma.org/2023-gina-main-report/</a> (Accessed on May 19, 2023). Reproduced with permission from: Global Initiative for Asthma. Asthma Management and Prevention (for Adults and Children Older than 5 Years): A Pocket Guide for Health Professionals, Updated 2019. Available at: <a href="https://ginasthma.org/pocket-guide-for-asthma-management-and-prevention/" target="_blank">https://ginasthma.org/pocket-guide-for-asthma-management-and-prevention/</a> (Accessed on July 19, 2019).</div><div id="graphicVersion">Graphic 53233 Version 8.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
